Piotr Radojewski

发表

Somatostatin Receptor–Targeted Radiopeptide Therapy with 90Y-DOTATOC and 177Lu-DOTATOC in Progressive Meningioma: Long-Term Results of a Phase II Clinical Trial

M. Briel, M. Walter, J. Müller-Brand, 2015, The Journal of Nuclear Medicine.

Survival after somatostatin based radiopeptide therapy with (90)Y-DOTATOC vs. (90)Y-DOTATOC plus (177)Lu-DOTATOC in metastasized gastrinoma.

C. Rochlitz, M. Briel, M. Walter, 2015, American journal of nuclear medicine and molecular imaging.

BRIEF COMMUNICATION Somatostatin receptor targeted radiopeptide therapy with yttrium-90-DOTATOC and lutetium-177-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial

M. Briel, M. Walter, P. Radojewski, 2015 .

Upregulation of Key Molecules for Targeted Imaging and Therapy

M. Walter, C. Stettler, P. Radojewski, 2016, The Journal of Nuclear Medicine.

Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis

M. Briel, E. Christ, M. Walter, 2019, JAMA oncology.

The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors

L. Bubendorf, M. Briel, M. Walter, 2017, European Journal of Nuclear Medicine and Molecular Imaging.

MEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer

M. Walter, W. Phillips, P. Radojewski, 2018, The Journal of Nuclear Medicine.

Diabetes Mellitus and Its Effects on All-Cause Mortality After Radiopeptide Therapy for Neuroendocrine Tumors

M. Walter, J. Beyersmann, M. Laimer, 2017, The Journal of Nuclear Medicine.

Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis.

M. Briel, E. Christ, M. Walter, 2021, The Cochrane database of systematic reviews.

Towards tailored radiopeptide therapy

M. Briel, M. Walter, P. Radojewski, 2015, European Journal of Nuclear Medicine and Molecular Imaging.